Literature DB >> 25473180

Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors.

Yihebali Chi1, Feng Du1, Hong Zhao1, Jin-Wan Wang1, Jian-Qiang Cai1.   

Abstract

AIM: To analyze the clinicopathologic characteristics and prognostic factors of rectal neuroendocrine tumors.
METHODS: The records of 48 patients with rectal neuroendocrine tumors who were treated at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, from March 2004 to September 2009 were retrospectively reviewed. The clinicopathological data were extracted and analyzed, and patients were followed-up by telephone or follow-up letter to determine their survival status. Follow-up data were available for all 48 patients. Uni- and multivariate Cox regression analyses were performed to determine the prognostic factors significantly associated with overall survival.
RESULTS: The tumors occurred mostly in the middle and lower rectum, and the most prominent symptoms experienced by patients were hematochezia and diarrhea. The median distance between the tumors and the anal edges was 5.0 ± 2.257 cm, and the median diameter of the tumors was 0.8 ± 1.413 cm. The major pathological type was a typical carcinoid tumor, which accounted for 93.8% (45/48) of patients. Tumor-node-metastasis (TNM) stages I, II, III and IV tumors accounted for 78.8%, 3.9%, 9.6% and 7.7% of patients, respectively. The main treatment method, in 72.9% (35/48) of patients, was transanal extended excision. The 1-, 3- and 5-year survival rates of the whole group of patients were 100%, 93.7%, and 91.3%, respectively. Univariate analysis showed that age (P = 0.032), tumor diameter (P < 0.001), histological type (P < 0.001), TNM stage (P < 0.001), and surgical approach (P = 0.002) were all prognostic factors. On multivariate analysis, only the pathological type was shown to be an independent prognostic factor (HR = 2.797, 95%CI: 1.676-4.668, P = 0.004).
CONCLUSION: In patients with rectal neuroendocrine tumors, TNM stage I is the most common stage found, and lymph node or distant metastases are rarely seen. The pathological type of the tumor is an independent prognostic factor.

Entities:  

Keywords:  Clinical characteristics; Prognostic factors; Rectal neuroendocrine tumors

Mesh:

Year:  2014        PMID: 25473180      PMCID: PMC4239514          DOI: 10.3748/wjg.v20.i43.16252

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Clinical outcomes for rectal carcinoid tumors according to a new (AJCC 7th edition) TNM staging system: a single institutional analysis of 122 patients.

Authors:  Min Sung Kim; Hyuk Hur; Byung Soh Min; Seung Hyuk Baik; Kang Young Lee; Nam Kyu Kim
Journal:  J Surg Oncol       Date:  2013-03-15       Impact factor: 3.454

2.  Treatment strategy for rectal carcinoids: a clinicopathological analysis of 229 cases at a single cancer institution.

Authors:  Akiyoshi Kasuga; Akiko Chino; Naoyuki Uragami; Teruhito Kishihara; Masahiro Igarashi; Rikiya Fujita; Noriko Yamamoto; Masashi Ueno; Masatoshi Oya; Tetsuichiro Muto
Journal:  J Gastroenterol Hepatol       Date:  2012-12       Impact factor: 4.029

3.  Long term outcomes of neuroendocrine carcinomas (high-grade neuroendocrine tumors) of the colon, rectum, and anal canal.

Authors:  E Aytac; Y Ozdemir; G Ozuner
Journal:  J Visc Surg       Date:  2014-01-08       Impact factor: 2.043

Review 4.  Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature.

Authors:  M Fraenkel; M Kim; A Faggiano; W W de Herder; G D Valk
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

5.  Surveillance strategy for rectal neuroendocrine tumors according to recurrence risk stratification.

Authors:  Dong Hyun Kim; Jin Ha Lee; Yoon Jin Cha; Soo Jung Park; Jae Hee Cheon; Tae Il Kim; Hoguen Kim; Won Ho Kim; Sung Pil Hong
Journal:  Dig Dis Sci       Date:  2013-12-10       Impact factor: 3.199

6.  Clinical outcomes of rectal neuroendocrine tumors ≤ 10 mm following endoscopic resection.

Authors:  Gwang-Un Kim; Kyung-Jo Kim; Seung-Mo Hong; Eun-Sil Yu; Dong-Hoon Yang; Kee Wook Jung; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang; Jin-Ho Kim
Journal:  Endoscopy       Date:  2013-11-28       Impact factor: 10.093

7.  Endoscopically identified well-differentiated rectal carcinoid tumors: impact of tumor size on the natural history and outcomes.

Authors:  Ferga C Gleeson; Michael J Levy; Eric J Dozois; David W Larson; Louis Michel Wong Kee Song; Lisa A Boardman
Journal:  Gastrointest Endosc       Date:  2014-01-23       Impact factor: 9.427

8.  Neuroendocrine tumors of the colon and rectum: prognostic relevance and comparative performance of current staging systems.

Authors:  Ryaz Chagpar; Yi-Ju Chiang; Yan Xing; Janice N Cormier; Barry W Feig; Asif Rashid; George J Chang; Y Nancy You
Journal:  Ann Surg Oncol       Date:  2012-12-01       Impact factor: 5.344

9.  Clinical and prognostic features of rectal neuroendocrine tumors.

Authors:  Brett Weinstock; Stephen C Ward; Noam Harpaz; Richard R P Warner; Steven Itzkowitz; Michelle Kang Kim
Journal:  Neuroendocrinology       Date:  2013-11-05       Impact factor: 4.914

10.  Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany.

Authors:  Hans Scherübl; Brigitte Streller; Roland Stabenow; Hermann Herbst; Michael Höpfner; Christoph Schwertner; Joachim Steinberg; Jan Eick; Wanda Ring; Krishna Tiwari; Sören M Zappe
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

View more
  7 in total

1.  Primary carcinoid tumor of the kidney with estrogen and progesterone receptor expression.

Authors:  Chunhua Lin; Jitao Wu; Zhenli Gao; Guimei Qu; Wei Wang; Guohua Yu
Journal:  Oncol Lett       Date:  2015-04-30       Impact factor: 2.967

2.  Clinical characteristics, risk factors and outcomes of asymptomatic rectal neuroendocrine tumors.

Authors:  Sun-Hye Ko; Myong Ki Baeg; Seung Yeon Ko; Hee Sun Jung
Journal:  Surg Endosc       Date:  2017-01-11       Impact factor: 4.584

3.  Analysis of the factors affecting lymph node metastasis and the prognosis of rectal neuroendocrine tumors.

Authors:  Peng Li; Fan Wu; Hong Zhao; Lizhou Dou; Yang Wang; Chunguang Guo; Guiqi Wang; Dongbing Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 4.  Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.

Authors:  Peter E Goretzki; Martina T Mogl; Aycan Akca; Johann Pratschke
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

5.  Nomogram for individually predicting overall survival in rectal neuroendocrine tumours.

Authors:  Xingyu Feng; Gengzhou Wei; Wei Wang; Yu Zhang; Yujie Zeng; Minhu Chen; Ye Chen; Jie Chen; Zhiwei Zhou; Yong Li
Journal:  BMC Cancer       Date:  2020-09-09       Impact factor: 4.430

6.  Long-term outcomes according to additional treatments after endoscopic resection for rectal small neuroendocrine tumors.

Authors:  Jae Hwang Cha; Da Hyun Jung; Jie-Hyun Kim; Young Hoon Youn; Hyojin Park; Jae Jun Park; Yoo Jin Um; Soo Jung Park; Jae Hee Cheon; Tae Il Kim; Won Ho Kim; Hyun Jung Lee
Journal:  Sci Rep       Date:  2019-03-20       Impact factor: 4.379

7.  Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: A single-center study.

Authors:  Lijie Song; Xuejia Zhai; Shunli Yu; Yihui Ma; Feng Wang; Xuxu Yu; Shuang Tao; Yujin Lian; Minjie Yang; Weili Tao; Qingxia Fan
Journal:  Cancer Med       Date:  2019-05-24       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.